Navigation Links
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
Date:6/3/2008

ith XIAFLEX. For placebo patients, the average percent improvement in primary joint contracture from baseline was 13.6% (50 degrees average contracture at baseline down to an average 44.3 degrees after placebo treatment) (p<0.001). A >/= 50% reduction from baseline in the affected joint's contracture was achieved in 77.8% of patients (35 of 45) of all primary joints treated with XIAFLEX compared to 14.3% of patients (3 of 21) for joints treated with placebo (p<0.001).

Top-line Efficacy Results of CORD I and CORD II

XIAFLEX arm Placebo arm p-value

CORD I:

Number of evaluable subjects 203 103

Percentage of contractures 64% 6.8% <0.001

achieving

Average percent improvement in 79.3% 8.6% <0.001

contracture from baseline (50.2 deg./ (49.1 deg./

12.2 deg.) 45.7 deg.)

Percentage of contractures 84.7% 11.7% <0.001

achieving >/= 50% reduction (172/203) (12/103)

CORD II:

Number of evaluable subjects 45 21

Percentage of contractures 44.4% 4.8% <0.001

achieving

Average percent improvement 70.5% 13.6% <0.001

in contracture from baseline (53.2 deg./ (50.0 deg./

16.7 deg.) 44.3 deg.)

Percentage of contractures 77.8% 14.3% <0.001

achieving >/= 50% reduction (35/45) (3/21)

Note: All data applies to primary joint 30 days after last injection

"As described in the available literature on surgery and as we have seen in previous XIAFLEX clinical studies, the CORD I and II trial
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , N.J. and NEW PROVIDENCE, N.J. ... experts will present a paper on the critical ... medical oxygen storage and deliver systems at the American ... will be held at the Chicago Sheraton Hotel and ... Derrick West , program manager of ...
(Date:9/15/2014)...  Bayer HealthCare and Orion Corporation, a pharmaceutical ... , have begun to enroll patients in a ... androgen receptor inhibitor in clinical development. The study, ... prostate cancer who have rising Prostate Specific Antigen ... is designed to determine the effects of the ...
(Date:9/15/2014)... WALTHAM, Mass. , Sept. 15, 2014  Alere Inc. ... a global leader in infectious disease, toxicology, cardiology and ... of former executives, led by former CEO Ron ... and Exchange Commission and subsequently sent a letter to ... requesting one month of due diligence in an effort ...
Breaking Medicine Technology:Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 2Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 3Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Alere Responds To Letter From Former Executives 2
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... has successfully completed the validation phase of the Unifill® ... final step in the industrialization process for the Unifill ... said: "The completion of all validation tests associated with ...
... Cayenne Medical, Inc., a private sports medicine device ... System, its second generation device for treatment of traumatic ... the 2011 American Orthopaedic Society for Sports Medicine Annual ... Tal David, MD, orthopedic sports medicine specialist, San ...
Cached Medicine Technology:Unilife Successfully Completes Industrialization of Unifill Syringe 2Unilife Successfully Completes Industrialization of Unifill Syringe 3Unilife Successfully Completes Industrialization of Unifill Syringe 4Cayenne Medical, Inc. Launches CrossFix® II Meniscal Repair System 2
(Date:9/16/2014)... in cancer patients suffering from malignant spinal cord compression ... of radiation therapy (RT), compared to patients who receive ... according to research presented today at the American Society ... Malignant spinal cord compression (MSCC) is a complication of ... a tumor,s secondary deposit presses on the spinal cord ...
(Date:9/16/2014)... Umpires and judges are the unwitting focus of some ... and gymnasts to improve their performance in competition, thanks ... researcher. , Dr Daniel Greenwood, from QUT,s Institute of ... Academy of Sport Centre of Excellence for Applied Sport ... in sports such as cricket, long jump, triple jump ...
(Date:9/16/2014)... Beginning October 1st 2014, Dallas’ Park Cities Pet ... clients who book a recurring visit schedule, and thus receive ... Most recurring visit clients are ones that book ... include clients whose unique work schedules or lifestyles simply require ... basis. The newly introduced 15-minute visit length will only ...
(Date:9/16/2014)... York (PRWEB) September 16, 2014 Transparency ... states that the global facial care market is expected ... 2019. The report, titled ‘Facial Care Market (By Product ... Face Wash, Cleansing Wipes, Serums and Masks and Others ... Size, Share, Growth, Trends and Forecast 2013 – 2019,’ ...
(Date:9/16/2014)... Whatisfinalexpenseinsurance.com has released a new blog post ... seniors. , Finding affordable life insurance for senior citizens ... the insurance market has moved online. The newly released ... use when shopping for life coverage. , Having ... financial security for vulnerable family members. Clients can use ...
Breaking Medicine News(10 mins):Health News:Cancer patients with malignant spinal cord compression have preserved mobility 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 4Health News:Getting the jump on competitors: QUT study 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3Health News:Life Insurance for Seniors - Clients Can Find Fast Life Insurance By Comparing Online Quotes! 2
... life expectancy, study finds , TUESDAY, Feb. 23 ... MRI appears to be a cost-effective way to improve ... cancer, U.S. researchers say. , In the new study, ... in Boston, and colleagues used statistical modeling to compare ...
... ... ... ... ...
... stress hormone levels in adolescent boys and girls but ... researchers. Early treatment of depression could help reduce stress ... "This is the first time cortisol reactivity has ... obesity in girls," said Elizabeth J. Susman, the Jean ...
... ... ... , ... , , , , ...
... LOUIS -- The extract from a vegetable that is common ... of events that kills breast cancer cells and prevents them ... Ratna Ray, Ph.D., professor in the department of pathology at ... that the extract from the bitter melon she cooks in ...
... ... ... ... ...
Cached Medicine News:Health News:Mammogram Plus MRI Seems Cost-Effective in High-Risk Women 2Health News:First Coast Service Options (FCSO) Expands Use of Burgess Products 2Health News:First Coast Service Options (FCSO) Expands Use of Burgess Products 3Health News:First Coast Service Options (FCSO) Expands Use of Burgess Products 4Health News:Stress hormone, depression trigger obesity in girls 2Health News:Johnson & Johnson to Participate in RBC Capital Markets' Health Care Conference 2Health News:Bitter melon extract attacks breast cancer cells 2Health News:Kimberly-Clark Announces 10 Percent Dividend Increase 2Health News:Kimberly-Clark Announces 10 Percent Dividend Increase 3
Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 3 mm x 1.0 mm x 3.0 mm....
19 Gauge. Reusable. Block of 4 each....
18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Medicine Products: